Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics

Integra LifeSciences (IART) reported $415.61 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 0.6%. EPS of $0.45 for the same period compares to $0.63 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $395.64 million, representing a surprise of +5.05%. The company delivered an EPS surprise of +4.65%, with the consensus EPS estimate being $0.43.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic Revenue Growth: -1.4% compared to the -6.3% average estimate based on four analysts.
• Revenue- Codman Specialty Surgical- Total: $303.96 million compared to the $294.18 million average estimate based on four analysts. The reported number represents a change of +0.7% year over year.
• Revenue- Tissue Technologies- Total: $111.65 million versus $101.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.1% change.
• Revenue- Tissue Technologies- Wound Reconstruction and Care: $84.75 million compared to the $80.24 million average estimate based on two analysts. The reported number represents a change of -3.4% year over year.
• Revenue- Tissue Technologies- Private Label: $26.9 million versus the two-analyst average estimate of $25.3 million. The reported number represents a year-over-year change of -6.3%.

View all Key Company Metrics for Integra here>>>

Shares of Integra have returned -8.5% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research